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Abstract 
Background: The runt-related transcription factor 2 (Runx2) is a cell-fate-determining factor that controls osteoblast 
differentiation and bone formation. It has been previously demonstrated that microRNAs (miRNAs) play important 
roles in osteogenesis. However, the Runx2-regulated miRNAs that have been reported thus far are limited. In this 
study, we pursued to identify these miRNAs in Tet-on stable C2C12 cell line (C2C12/Runx2Dox subline).
Results: Microarray analysis revealed that alterations in miRNA expression occur with 54 miRNAs. Among these 
miRNAs, miR-690 was identified as a positive regulator of Runx2-induced osteogenic differentiation of C2C12 cells 
through gain- and loss-of-function assays. Expression of miR-690 is induced by Runx2, which binds directly to the 
putative promoter of mir-690 (Mirn690). The miR-690 proceeds to inhibit translation of the messenger RNA encoding 
the nuclear factor kappa B (NF-κB) subunit p65 whose overexpression inhibits Runx2-induced osteogenic differentia-
tion of C2C12 cells. Interleukin-6 (IL-6), a downstream target of NF-κB pathway, is upregulated by p65 overexpression 
but significantly downregulated during this differentiation process. Furthermore, overexpression of IL-6 impedes the 
expression of osteocalcin, a defined marker of late osteoblast differentiation.
Conclusions: Together, our results suggest that the miR-690 transactivated by Runx2 acts as a positive regulator of 
Runx2-induced osteogenic differentiation by inactivating the NF-κB pathway via the downregulation of the subunit 
p65.
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Background
The proper differentiation of mesenchymal progenitor 
cells into osteoblast lineage is pivotal for bone develop-
ment in  vivo. Osteoblast differentiation is governed by 
numerous regulatory pathways involving transcription 
factors, signaling molecules, and chromatin modifi-
ers [1–3]. In addition, posttranscriptional mechanisms 
including miRNA-mediated regulation also play impor-
tant roles in regulating osteogenic differentiation.
MicroRNAs (miRNAs) are small (approximately 22nt), 
functional, highly conserved, endogenous noncoding 
RNA. They regulate protein translation or mRNA sta-
bility by imperfect binding to the 3′ untranslated region 
(3′UTR) of their target genes. These small RNAs have 
emerged as key regulators of almost every biological pro-
cess in eukaryotes, including early development, growth 
and differentiation, and cell apoptosis. The impact of miR-
NAs on osteoblast differentiation has been investigated 
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in several studies. It has been shown that miR-135 targets 
the intracellular receptor SMAD family member 5 and 
inhibits bone morphogenetic protein 2(BMP-2)-induced 
osteogenic differentiation of C2C12 cells [4]. MiR-141 and 
its homolog miR-200a are involved in BMP-2-induced 
preosteoblast differentiation by regulating their common 
target distal-less homeobox 5 [5]. In primary mouse osteo-
blasts, miR-93 has been found to target osterix and then 
inhibits osteoblast mineralization [6]. MiR-204 and its 
homolog miR-211 stimulate adipocyte differentiation but 
inhibit osteoblast differentiation of bone marrow stromal 
cells through targeting runt-related transcription factor 2 
(Runx2) [7]. In addition, a panel of 11 miRNAs, including 
miR-204, has been found to control osteogenic lineage 
progression by targeting Runx2 [8]. These results suggest 
that the expression level of osteogenesis-related factors 
could be tightly controlled by miRNAs, which is an effec-
tive method for regulating osteogenesis. Additionally, the 
miRNAs controlled by these factors (especially the osteo-
blast-specific transcription factors) are also indispensable 
for regulating osteogenesis.
Runx2 (also known as Cbfa1, AML-3, and PEBP2aA), 
an osteoblast-specific transcription factor belonging to 
the runt-domain gene family [9], is expressed in mes-
enchymal condensations during early embryonic devel-
opment [10]. Many previous studies have revealed that 
during both embryogenesis and postnatal life, Runx2 
plays a key role in regulating osteoblast and hyper-
trophic chondrocyte differentiation, and bone forma-
tion [11–13]. The underlying mechanism by which 
Runx2 regulates these processes is still unclear, and the 
identification of Runx2-regulated miRNAs can provide 
new insight into the mechanism. However, Runx2-con-
trolled miRNAs that have been identified thus far are 
limited.
In the current study, we explored Runx2-regulated 
miRNAs by using C2C12/Runx2Dox subline previously 
described [14], and obtained 54 differentially expressed 
miRNAs during Runx2-induced osteogenic differen-
tiation, and identified miR-690 as a positive regulator 
during this differentiation process. Furthermore, we 
demonstrated that miR-690 is directly induced by Runx2. 
The nuclear factor kappa B (NF-κB) subunit p65 was 
identified as a direct target of miR-690, and its overex-
pression inhibits Runx2-induced osteogenic differentia-
tion. Interleukin-6 (IL-6), a downstream target of NF-κB 
pathway [15], is upregulated by p65 overexpression but 
significantly downregulated during this differentiation 
process. Furthermore, overexpression of IL-6 impedes 
Runx2-induced late osteoblast differentiation. Together, 
our findings suggest that Runx2 promotes osteogenic dif-
ferentiation of C2C12 cells by inactivating NF-κB path-
way via the upregulation of miR-690.
Results
Identification of differentially expressed miRNAs 
during Runx2‑induced osteogenic differentiation
Elucidating Runx2-regulated miRNAs could provide new 
insight into the mechanism whereby Runx2 functions in 
osteogenesis. Here, we used the C2C12/Runx2Dox sub-
line previously described [14] to explore this question. In 
C2C12/Runx2Dox cells, the expression of Flag-Runx2 can 
be tightly regulated by doxycycline (Dox) treatment. In 
the absence of Dox, the C2C12/Runx2Dox cells cultured in 
medium containing 2 % horse serum can be induced into 
multinucleated myotubes (Additional file 1: Figure S1A). 
Additionally, C2C12/Runx2Dox cells also can be induced 
into osteoblasts by BMP-2 treatment in the absence of 
Dox (Additional file 1: Figure S1B). These results suggest 
that the differentiation characteristics of C2C12/Runx-
2Dox cells is similar to that of C2C12 myogenic progenitor 
cells. Taken together, we believed that the C2C12/Runx-
2Dox cells are actually the wild type C2C12 myogenic pro-
genitor cells in the absence of Dox.
Osteogenic differentiation of C2C12 cells was evi-
denced by increased expression of genes associated with 
osteoblast differentiation, alkaline phosphatase (Alp) and 
osteocalcin (OC), at the indicated times after Dox treat-
ment (Fig. 1a). The expression of mRNA and protein for 
Flag-Runx2 was increased in a time-dependent manner 
(Fig. 1a, Additional file  2: Figure S2A). In immunocyto-
chemistry analysis, Flag-Runx2 was found to be mainly 
expressed in the nuclei of Dox-treated C2C12/Runx2Dox 
cells, and the percentage of cells overexpressing Flag-
Runx2 was also increased in a time-dependent manner 
(Additional file  3: Figure S3). The osteoblast phenotype 
was confirmed by demonstration of increased ALP activ-
ity and Alizarin Red staining for matrix mineralization 
(Fig.  1b). These results suggest that the C2C12/Runx-
2Dox subline works well. Moreover, the cell line harbor-
ing the empty vector (C2C12-empty vector Tet-on cell 
line, C2C12/vectorDox cells) was used to investigate and 
exclude the influence of Dox. As shown in Additional 
file 4: Figure S4, the ALP activity and matrix mineraliza-
tion were absent in Dox-treated C2C12/vectorDox cells. 
These results suggest that Dox itself has no effect on the 
osteogenic differentiation of C2C12 cells.
To detect miRNAs related to Runx2-induced osteo-
genic differentiation, miRNA profiling was performed by 
using total RNA from Dox-treated C2C12/Runx2Dox cells 
collected at 0, 3, 6, 9, 12, 24, 48, and 72 h. The values of 
the miRNA expression level at each time point were clus-
tered and graphically illustrated (Additional file 5: Figure 
S5). Expression levels of 54 miRNAs were altered during 
this differentiation process (Fig. 1c). Of these, 13 miRNAs 
were upregulated in the early induction phase (6–24 h), 
and declined to basal levels in the late induction phase 
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Fig. 1 A program of miRNAs is expressed during Runx2-induced osteogenic differentiation of C2C12 cells. a C2C12/Runx2Dox cells were treated 
with Dox for the times indicated (0–72 h). The mRNA level of Runx2, Alp, and OC was determined by real-time qPCR. All data are presented as the 
mean ± SD from three independent experiments. *P < 0.05, **P < 0.01 compared with untreated cells (0 h). b ALP and matrix mineralizing activity 
were measured by ALP and Alizarin red staining at days 7 and 28, respectively. Similar results were obtained in three independent experiments. c 
Differentially expressed miRNAs from miRNA microarray data. 54 miRNAs whose expression changed by ≥ 1.5-fold at least one time point were cho-
sen as the differentially expressed miRNAs by comparing with untreated cells (0 h), and these miRNAs were arranged by unsupervised hierarchical 
clustering. Data value displayed as red and green represent elevated (high) and reduced expression (low), respectively
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(48 and 72 h) (blue box in Fig. 1c). As shown in Fig. 1a 
and Additional file  2: Figure S2, C2C12/Runx2Dox cells 
were induced into osteoblasts by 12 h based on expres-
sion of muscle and bone phenotypic genes, suggesting the 
crucial role of early induction phase in Runx2-induced 
transdifferentiation of myoblasts (C2C12 cells) into the 
osteoblastic phenotype. Thus, for osteogenesis to pro-
ceed, there is a requirement for upregulation of the 13 
miRNAs in the dataset responsive to Runx2 overexpres-
sion to convert the differentiation pathway of C2C12 
myoblasts into the osteoblast lineage. We then focused 
our attention on these miRNAs.
Effect of miR‑690 on Runx2‑induced osteogenic 
differentiation
To evaluate the biological effect of the above-men-
tioned 13 miRNAs, anti-miRs and miRNA mimics for 
these miRNAs were used in a functional screening for 
their impact on Runx2-induced osteogenic differentia-
tion. Here, we identified miR-690 as a potential positive 
regulator of Runx2-induced osteogenic differentiation. 
Expression level of miR-690 was measured at different 
time points during this differentiation process. MiR-690 
was significantly upregulated at hour 6, and remained 
upregulated up to hour 24, and declined to basal levels 
at hour 48 and 72 respectively (Fig.  2a). Additionally, 
Dox itself also has no effect on the expression of miR-690 
(Additional file  6: Figure S6). The miR-690 expression 
change assayed by real-time quantitative PCR (qPCR) 
was generally similar to the change in miR-690 expres-
sion as determined by miRNA microarray (Fig. 1c).
To study the effect of miR-690 on Runx2-induced oste-
ogenic differentiation, we transfected miR control, miR-
690, anti-miR control, and anti-miR-690 into C2C12/
Runx2Dox cells, respectively, and found that transfection 
of miR-690 increased expression of Alp and OC (Fig. 2b), 
whereas transfection of anti-miR-690 reduced their 
expression (Fig. 2c). Moreover, ALP activity was slightly 
increased in miR-690-transfected C2C12/Runx2Dox cells 
(Fig. 2d). These findings demonstrate that miR-690 syner-
gistically potentiates Runx2-induced osteogenic differen-
tiation of C2C12 cells.
Mir‑690 is a direct transcriptional target of Runx2
Mir-690 expression can be rapidly induced following 
activation of Runx2 (Fig.  2a), raising the possibility that 
mir-690 is a direct target of Runx2. To test this hypoth-
esis, we first examined the −1  kb genomic sequence 
upstream of the mir-690 stem-loop to search for poten-
tial Runx2-binding site using TFSEARCH database [16] 
and ConSite program [17]. Indeed, we identified four 
potential sites at −313 to −305 (site 4, Runx2-4), −298 to 
−290 (site 3, Runx2-3), −246 to −238 (site 2, Runx2-2), 
and −64 to −56 (site 1, Runx2-1), respectively (Fig. 3a). 
With an electrophoretic mobility shift assay (EMSA), the 
labeled oligonucleotide containing Runx2-2 produced 
a significant shift (BS) in the Dox-treated cells nuclear 
extract (Fig.  3b, BS in lane 1), but the labeled oligonu-
cleotides containing Runx2-1, Runx2-3, or Runx2-4 
failed to do so (data not shown). No apparent shift was 
produced by the oligonucleotide containing Runx2-2 in 
the extract from non-treated cells (Fig.  3b, lane 8). The 
observed shift was abolished by 10- to 50-fold molar 
excess of unlabeled oligonucleotides (Fig. 3b, lanes 2–4). 
The labeled oligonucleotide contained a 9  bp mutation 
also abolished the shift (Fig. 3b, lane 7). Furthermore, the 
anti-Flag antibody, not the mouse IgG antibody, super-
shifted the complex (BS) (Fig. 3b, lanes 5 and 6), suggest-
ing the specificity of the interaction. Thus, the EMSA 
assay demonstrated that the mir-690 promoter contains 
one Runx2-binding site, Runx2-2.
Chromatin immunoprecipitation (ChIP) assay was 
performed to examine whether Runx2 interacts with 
mir-690 promoter in vivo. As shown in Fig. 3c, the anti-
Flag antibody specifically enriched the regions contain-
ing Runx2-2 (primer-1). By contrast, no positive signals 
were detected in various negative controls, including 
the PCR control (H2O) or immunoprecipitation control. 
Additionally, Runx2 did not associate with the unrelated 
part in the distal 5′ flanking region of the Runx2-2 site 
(primer-2). These results indicate that Runx2 binds to the 
mir-690 promoter in vivo. Together, these results suggest 
that Runx2 acts as a transcriptional activator on mir-690.
MiR‑690 directly targets p65 through translational 
inhibition
To understand the molecular mechanism that underlies 
miR-690-mediated regulation, we search for potential 
targets of miR-690 implicated in Runx2-induced osteo-
genic differentiation using the miRNA target prediction 
algorithms DIANA-microT, miRDB, and miRWalk [18–
20]. More than 100 genes were predicted to be potential 
target genes for miR-690. Among the predicted genes, 
we identified p65, a NF-κB subunit with a negative role 
in osteoblast differentiation [21]. According to in silicon 
analysis, p65 has two potential binding sites for miR-690 
within its 3′UTR (Fig. 4a). To investigate whether p65 can 
be directly targeted by miR-690, we engineered a lucif-
erase reporter that has wild-type 3′UTR of p65 (Fig. 4b). 
Co-transfection of the p65 3′UTR luciferase reporter 
with miR-690 resulted in downregulation of the lucif-
erase activity compared with the miR control (Fig. 4c). In 
comparison, miR-690-Mut had no effect on p65 3′UTR 
luciferase reporter (Fig. 4c), implying that p65 is a direct 
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target of miR-690. Thus, we further examined how miR-
690 repressed p65 expression. Real-time qPCR results 
revealed no significant change in p65 mRNA level when 
miR-690 was transfected into C2C12/Runx2Dox cells 
(Fig. 4d). However, Western blot result showed reduced 
p65 protein level in the miR-690-transfected cells com-
pared with miR control sample (Fig.  4e), indicating 
that miR-690 mediates translational repression but not 
mRNA degradation of p65. Additionally, the expression 
of p65 was slightly increased at the protein but not the 
mRNA level in the anti-miR-690-transfected cells com-
pared with anti-miR control sample (Additional file  7: 
Figure S7). Together, these results indicate that miR-690 
directly targets p65 through translational inhibition.
p65 exerts its effect on Runx2‑induced osteogenic 
differentiation partially through IL‑6 upregulation
Since p65 is directly targeted by miR-690, it was neces-
sary to examine whether p65 exerts an opposite effect 
on Runx2-induced osteogenic differentiation as com-
pared with miR-690. p65 expression vector was used for 
transfection of C2C12/Runx2Dox cells, followed by Dox 
treatment for 3 days. Real-time qPCR data revealed that 
p65 overexpression attenuates the expression of Alp and 
OC (Fig.  5a), suggesting that p65 is a negative regula-
tor of Runx2-induced osteogenic differentiation. Addi-
tionally, the mRNA level of p65 was unchanged during 
this differentiation process (Additional file  8: Figure 
S8A). However, the protein level of p65 was decreased 
Fig. 2 miR-690 synergistically potentiates Runx2-induced osteogenic differentiation. a Real-time qPCR analysis of miR-690 was performed in 
Dox-treated samples used for miRNA profiling analysis. b, c Effect of miR-690 on expression of osteoblastic markers. C2C12/Runx2Dox cells were 
transfected with miR control (b), miR-690 (b), anti-miR control (c), and anti-miR-690 (c), respectively, and then treated with Dox for 3 days. The mRNA 
level of Alp and OC was measured by real-time qPCR. *P < 0.05 compared with miR control or anti-miR control samples. d Effect of miR-690 on ALP 
activity. C2C12/Runx2Dox cells were transfected with miR control and miR-690, respectively, and then treated with Dox for 7 days. The ALP activity 
was determined by ALP staining. Similar results were obtained in three independent experiments
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in Dox-treated C2C12/Runx2Dox cells at hour 12, possi-
bly resulting from the high level of miR-690 at this time 
point (Additional file 8: Figure S8B). This finding shows 
that p65 is indeed a direct target of miR-690 during this 
differentiation process.
Previous studies have shown that IL-6 is a direct tran-
scriptional target of NF-κB [15], and that osteoblast dif-
ferentiation can be negatively regulated by IL-6 [22]. 
This observation raised the possibility that p65 may 
exert its negative effect on Runx2-induced osteogenic 
differentiation by upregulating IL-6. We therefore per-
formed a series of experiments to investigate this pos-
sibility. IL-6 expression was found to be upregulated in 
C2C12/Runx2Dox cells transfected with p65 expression 
vector in the presence of Dox for 3 days (Fig. 5b). In the 
absence of Dox, IL-6 expression was also upregulated 
Fig. 3 miR-690 is directly regulated by Runx2. a Schematic representation of mouse mir-690 genomic locus, which indicates the locations of the 
four potential Runx2-binding sites. The italic letters indicate the core sequence of each site. b EMSA shows the interaction between mir-690 site 
(Runx2-2) and Runx2 in Dox-treated cells. The bottom arrow indicates the DNA–protein complex (BS). The top arrow indicates the Runx2-supershifed 
complex. WT wild-type, Mut mutant. c ChIP analysis was performed to confirm the interaction of Runx2 with mir-690 promoter in vivo. PCR was per-
formed with primer-1, which was designed to amplify a fragment of the mir-690 promoter flanking the Runx2-2 site. The primer-2 for an unrelated 
part (−1800/− 1653) in the distal 5′ flanking region of the Runx2-2 site was utilized for the control reaction in this ChIP analysis
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by p65 overexpression (Additional file  9: Figure S9). 
These results suggest that IL-6 could be activated by 
p65 during this differentiation process. To further verify 
the above-mentioned possibility, we also examined the 
mRNA level of IL-6 in Dox-treated C2C12/Runx2Dox 
cells, and found that the expression of IL-6 was signifi-
cantly downregulated (Fig.  5c), implying the negative 
effect of IL-6 on Runx2-induced osteogenic differen-
tiation. In addition, the role of IL-6 in the differentia-
tion process of C2C12/Runx2Dox cells was examined 
by transfection of IL-6 expression vector. As shown in 
Fig.  5d, the expression of OC, a defined marker of late 
osteoblast differentiation, was significantly downregu-
lated by IL-6 overexpression. However, the expression 
of Alp, a marker of early osteoblast differentiation, was 
not affected. Additionally, the negative effect of p65 on 
the expression of OC was attenuated in si-IL-6-trans-
fected C2C12/Runx2Dox cells compared with si-NC 
sample (Additional file 10: Figure S10). Taken together, 
these results indicate that p65 exerts its negative effect 
on Runx2-induced osteogenic differentiation partially 
through IL-6 upregulation.
Fig. 4 miR-690 directly targets p65. a Schematic representing miR-690 target sites in p65 3′UTR and base-pairing of miR-690 sequences with the 
3′UTR. b Schematic diagram illustrating the design of luciferase reporter with p65 3′UTR. The sequences of miR-690 and miR-690-Mut are also 
shown. The underlined sequences represent wild-type and mutated seed sequences of miR-690. Rluc Renilla luciferase, Luc Firefly luciferase, pA 
polyadenylation signal. c miR control, miR-690, or miR-690-mut was co-transfected with psiCHECK-2-p65 3′UTR reporter into C2C12/Runx2Dox cells. 
After 48 h, cells were harvested and luciferase activities were measured. Luciferase activity = (Renilla/Firefly) ratio. Renilla, raw renilla luciferase activ-
ity; Firefly, firefly luciferase activity. Data are presented as mean ± SD (n = 3). *P < 0.05 compared with miR control sample. d, e Relative mRNA level 
of p65 (d) and protein level of p65 (e) in miR control- or miR-690-transfected cells
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Discussion
In the present study, we reported an extensive 
genomic-wide profiling of miRNA expression during 
Runx2-induced osteogenic differentiation, and identi-
fied 54 differentially expressed miRNAs. MiR-690, a 
newly identified Runx2-targeted miRNA, was found 
to promote Runx2-induced osteogenic differentiation 
through translational inhibition of its target p65, per-
mitting the downregulation of the expression of p65 
downstream targets (IL-6 and other undisclosed tar-
gets); this favours, in turn, Runx2-induced osteogenic 
differentiation (Fig. 6).
Fig. 5 p65 exerts its effect on Runx2-induced osteogenic differentiation partially through IL-6 upregulation. a, b The empty vector (pcDNA3.1) 
or p65 expression vector (pcDNA3.1-p65) was transfected into C2C12/Runx2Dox cells. The transfected cells were treated with Dox for 3 days and 
subjected to real-time qPCR analysis for Alp (a), OC (a) and IL-6 (b) mRNAs, respectively. Data are presented as mean ± SD (n = 3). *P < 0.05 
compared with pcDNA3.1-transfected cells. Western blot was performed to assess the overexpression level of p65 (a, inset). c Real-time qPCR 
results of IL-6 in Dox-treated cells. Data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01 compared with untreated cells (0 h). d The empty 
vector (pcDNA3.1) or IL-6 expression vector (pcDNA3.1-IL-6) was transfected into C2C12/Runx2Dox cells. The transfected cells were treated with 
Dox for 3 days and subjected to real-time qPCR analysis for Alp and OC mRNAs. Data are presented as mean ± SD (n = 3). *P < 0.05 compared with 
pcDNA3.1-transfected cells
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Balint et al. have demonstrated that induction of osteo-
genic differentiation of C2C12 cells by BMP-2 could be 
separated into several distinct stages, and that the 8–12 h 
window may make the point of osteoblast phenotypic 
determination, and that the bone phenotype can be fur-
ther established from 16 to 24  h [23]. These results are 
consistent with the finding reported by Li et al. [4]. In our 
study, the commitment of C2C12 myoblasts to the oste-
ogenic phenotype is recognized by 12  h but not by 8  h 
(Fig.  1a). The discrepancy between BMP-2- and Runx2-
induced systems might arise from the different osteo-
genic effect of BMP-2 and Runx2 on C2C12 cells. Taken 
together, we concluded that the period from 12 to 24 h 
appears to be a point of osteoblast phenotypic determi-
nation, and that the period from 24 to 72 h might be used 
for further establishing bone phenotype during Runx2-
induced osteogenesis.
Many researches have shown that miRNAs play an 
important role in regulating osteoblast differentiation 
and bone formation [24]. A panel of miRNAs has been 
reported to control osteogenesis by targeting the cell-
fate-determining transcription factor Runx2 [8], but 
the Runx2-regulated miRNAs that have been identified 
are still limited (e.g., miR-2861-3960 cluster) [25]. In 
this study, we performed a miRNA microarray by using 
total RNA from Dox-treated C2C12/Runx2Dox cells, and 
identified 54 differentially expressed miRNAs regulated 
by Runx2. During Runx2-induced osteogenic differen-
tiation of C2C12 cells, the microarray data could reveal 
the followings: First, 19 miRNAs were upregulated and 
35 miRNAs were downregulated during osteogenic dif-
ferentiation from 609 mouse miRNAs on the array. Sec-
ond, the 35 downregulated miRNAs were predicted to 
target mainly regulatory factors that function to promote 
myogenesis and inhibit osteogenesis independently. MiR-
206, a significantly downregulated miRNA in microar-
ray data (Fig.  1c), was reported to be a muscle-specific 
miRNA and to promote myoblast differentiation by 
directly targeting paired box 7 [26, 27]. MiR-466f-3p and 
miR-125a-5p, whose expression were also downregulated 
(Fig.  1c), were found to be significantly downregulated 
during osteogenic differentiation of bone marrow- and 
adipose tissue-derived mesenchymal stem cells [28, 29], 
suggesting the general role of these miRNAs in the inhi-
bition of osteoblast differentiation. However, the bona 
fide targets of these miRNAs are still unclear during 
osteogenesis. Third, the 19 upregulated miRNAs could 
be divided into two categories: 13 miRNAs whose 
expression was upregulated in the early induction phase 
(6-24 h) but declined to basal levels in the late induction 
phase (48 and 72 h) (blue box in Fig. 1c), and 6 miRNAs 
whose expression was only significantly upregulated in 
the late induction phase (48 and 72 h) (red box in Fig. 1c). 
The distinct expression pattern of 19 upregulated miR-
NAs revealed that these miRNAs might exert differ-
ent effect on Runx2-induced osteogenic differentiation. 
MiR-21a-5p, miR-762, and miR-1224, belonging to the 
6 upregulated miRNAs, were reported to be involved in 
bone matrix mineralization [30–32], suggesting that the 6 
upregulated miRNAs might participate in the regulation 
of Runx2-induced late osteoblast differentiation.
Here, we concluded that the 13 upregulated miRNAs 
might play a key role in the commitment of C2C12 cells 
into osteoblastic lineage. To evaluate the biological effect 
of the 13 upregulated miRNAs on Runx2-induced oste-
ogenic differentiation, anti-miRs and miRNA mimics 
for these miRNAs were used in a functional screening. 
Finally, the screening identified miR-690 as a candidate 
regulator of Runx2-induced osteogenic differentiaition. 
Previous study has reported that miR-690 might play 
an important role in glucose regulation of β-cell func-
tion [33]. MiR-690 is highly overexpressed in functional 
myeloid-derived suppressor cells (MDSCs) and manipu-
lates MDSC activity by repressing transcription factor 
CCAAT/enhancer-binding protein α in inflammatory 
diseases as well as cancer [34, 35]. MiR-690 can also 
regulate fibroblast migration and dermal wound repair 
by directly targeting Versican [36]. In addition, miR-690 
was found to be involved in granulopoiesis [37], gluta-
mate-induced excitotoxicity [38], and regulating testos-
terone signaling in liver [39]. However, the function of 
miR-690 in regulating osteogenic differentiation was not 
clear. In this study, data obtained from in  vitro experi-
ments revealed that miR-690 overexpression enhances 
Runx2-induced osteogenic differentiation of C2C12 cells, 
whereas knockdown of miR-690 leads to the opposite 
effect (Fig. 2b–d). These findings suggest that miR-690 is 
Fig. 6 Proposed model for the regulation and function of miR-690 
during Runx2-induced osteogenic differentiation. Chr chromosome, 
RISC RNA-induced silencing complex
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an osteogenesis-related miRNA and positively regulates 
Runx2-induced osteogenic differentiation.
As shown in Fig.  2a, miR-690 expression was rapidly 
induced following activation of Runx2, suggesting that 
the transcriptional activation of mir-690 is dependent 
upon Runx2 expression. It further suggested that mir-690 
may be a direct target of Runx2. To define the molecular 
mechanism by which Runx2 regulates the expression of 
miR-690, we performed in silico analysis and identified 
four potential Runx2-binding sites in the −1 kb genomic 
sequence upstream of the mir-690 stem loop (Fig.  3a). 
EMSA analysis using nuclear extract from Dox-treated 
C2C12/Runx2Dox cells demonstrated specific binding 
of Runx2 for the Runx2 motif at position −246 (site2, 
Runx2-2)(Fig.  3b). However, the data obtained from 
these artificial in vitro systems may not necessarily reflect 
the regulation and function of the endogenous gene. To 
address this concern, we used ChIP analysis to corrobo-
rate the EMSA data. This study clearly demonstrated 
that Runx2 is specifically associated with the putative 
promoter of mir-690 during osteogenic differentiation 
of C2C12 cells (Fig.  3c). Together, our findings reveal 
that mir-690 could be a direct target of Runx2 during 
osteogeneis.
To study the molecular mechanism by which miR-690 
regulates Runx2-induced osteogenic differentiation, we 
searched for potential target genes that have an estab-
lished function in inhibiting osteogenesis. Interestingly, 
the 3′UTR of p65 possesses two match sites to the miR-
690 seed region. p65, a subunit of NF-κB, which can 
function either as a homodimer or as a classical het-
erodimer with the p50 subunit of NF-κB [40]. Indeed, 
p65 3′UTR luciferase reporter assays confirmed that 
p65 is a direct target of miR-690 (Fig.  4c). We showed 
that miR-690 mediates translational repression but not 
mRNA degradation of p65 (Fig.  4d, e). Overexpression 
of p65 inhibits Runx2-induced osteogenic differentia-
tion (Fig. 5a), and the effect of p65 on Runx2-induced late 
osteoblast differentiation is partially mediated through 
upregulating the NF-κB downstream target IL-6 (Figs. 5, 
6). In this study, the target that mediates the effect of 
p65 on Runx2-induced early osteoblast differentiation 
was not investigated, and other previously reported (e.g. 
IL-8, ICAM-1, miR-17, miR-21, miR-27b, and miR-30b) 
[41–43] or undisclosed targets might participate in this 
process.
It has been reported that p65 can inhibit BMP-2-in-
duced osteogenic differentiation by decreasing the DNA 
binding of the Smad complex [21]. Tumor necrosis fac-
tor alpha (TNFα), a proinflammatory cytokine, can exert 
its negative effect on osteoblast differentiation and bone 
formation through the NF-κB p50/p65 heterodimer 
[40]. Runx2 stability can be reduced by TNFα through 
upregulation of E3 ubiquitin ligases Smad ubiquitin regu-
latory factor 1 [44]. WW domain containing E3 ubiquitin 
protein ligase 1, which was significantly upregulated in 
mesenchymal stem cells (MSCs) from TNFα-transgenic 
mice [45], was found to be recruited by Schnurri-3 and to 
mediate Runx2 degradation in a ubiquitin–proteasome-
dependent manner [46]. MiR-3077-5p, a miRNA upregu-
lated by TNFα in MSCs from osteoporosis bone marrow 
of mice, was demonstrated to directly target Runx2 and 
to inhibit Runx2 translation [47]. These findings raise 
the possibility that Runx2 function could be negatively 
regulated by the NF-κB p50/p65 heterodimer. Thus, it is 
necessary to inactivate the canonical NF-κB pathway by 
Runx2 through miR-690-mediated downregulation of 
p65 during this differentiation process.
In addition, other undisclosed miR-690 targets may 
contribute to the phenotypic effects observed on inhibi-
tion or overexpression of miR-690. There are more than 
100 predicted targets for miR-690 in DIANA-microT, 
miRDB, and miRWalk [18–20], some of which are very 
relevant in the process of osteoblast differentiation and 
bone formation (e.g., Bcl2, Igfbp5, Smad7, Crem, Stat3, 
and Mmp28). The involvement of other potential osteo-
genic targets should be elucidated in future studies.
Conclusions
Taken together, our study provides a comprehensive 
profiling of Runx2-regulated miRNAs during osteogenic 
differentiation of C2C12 myogenic progenitor cells. MiR-
690, a newly identified Runx2-targeted miRNA, exerts 
its positive effect on Runx2-induced osteogenic differen-
tiation by inactivating the NF-κB pathway via the down-
regulation of the NF-κB subunit p65. Our findings enrich 
the knowledge of the Runx2-centered regulatory network 
that functions in osteoblast differentiation and bone for-




All primers and probes are available in Additional file 11: 
Tables S1–S7.
Cell culture
The establishment of C2C12/Runx2Dox sub-line has 
been described previously [14]. C2C12/Runx2Dox cells 
were maintained in Dulbecco’s modified Eagle medium 
(DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented 
with 10 % Tet System Approved fetal bovine serum (FBS) 
(Clontech, Mountain View, CA, USA). Hygromycin B 
and G418 were purchased from Invitrogen and added 
into the medium at the concentration of 500 μg/ml and 
800  μg/ml, respectively. For osteogenic differentiation, 
Page 11 of 14Yu et al. Cell Biosci  (2016) 6:10 
the C2C12/Runx2Dox cells were cultured in medium con-
taining Dox (10  μg/ml) (Clontech) and BMP-2 (100  ng/
ml) (R&D Systems, Minneapolis, MN, USA) respectively. 
For myogenic differentiation, C2C12/Runx2Dox cells 
were grown in growth medium consisting of high-glu-
cose DMEM supplemented with 10  % FBS (Invitrogen). 
At 80–90  % confluence, myogenic differentiation was 
induced by replacing the growth medium with differen-
tiation medium consisting of DMEM supplemented with 
2 % horse serum (Invitrogen). Additionally, the establish-
ment and culture of C2C12/VectorDox cells were similar 
to that of C2C12/Runx2Dox cells.
MiRNA microarray analysis
Total RNA containing small RNA was extracted from 
Dox-treated C2C12/Runx2Dox cells by using a mirVana 
miRNA Isolation Kit (Ambion, Austin, TX, USA). MiRNA 
profiling was performed using GeneChip miRNA Array 
version 1.0 (Affymetrix, Santa Clara, CA, USA). The 
array comprised 6703 mature microRNA sequences of 
71 organisms from the Sanger miRNA database (V.11) 
and an additional 922 encompassed human snoRNAs and 
scaRNAs (from Ensembl database and snoRNABase).
Microarray experiments were performed according to 
the manufacturer’s instructions. Briefly, 1 μg total RNA 
was labeled with Biotin FlashTag Biotin Labeling Kit 
(Affymetrix). The labeling reaction was hybridized on 
the miRNA Array in Affymetrix Hybridization Oven 640 
(Affymetrix) at 48  °C for 16 h. The arrays were stained 
with Fluidics Station 450 using fluidics script FS450_0003 
(Affymetrix), and then scanned on a GeneChip microar-
ray scanner (Affymetrix).
Microarray data analysis
MiRNA probe outliers were defined as per the manufac-
turer’s instructions (Affymetrix) and further analyzed for 
data summarization, normalization and quality control 
by using the miRNA QC Tool software (www.affymetrix.
com). To select the differentially expressed miRNAs, we 
used threshold values of ≥1.5 and ≤−1.5-fold change 
and a FDR significance level of <5 %. The data was Log2 
transformed and median centered by miRNAs using the 
Adjust Data function of CLUSTER 3.0 software (Michiel 
de Hoon, Human Genome Center, University of Tokyo, 
Tokyo, Japan), then further analyzed with hierarchical 
clustering with average linkage. Finally, we performed 
tree visualization by using Java Treeview (Stanford Uni-
versity School of Medicine, Stanford, CA, USA).
Reverse transcription PCR
Total RNA was extracted by Trizol reagent (Invitrogen). 
A 20  μl reaction mixture containing 1  μg of total RNA 
was reversely transcribed to cDNA using RT Ace reverse 
transcriptase (Toyobo, Osaka, Japan). Real-time qPCR was 
performed on the cDNA to examine the expression levels 
of mRNAs and miRNAs. The PCR reaction mix was pre-
pared using SYBR Green PCR Master Mix (Takara, Shiga, 
Japan). PCR conditions were as follows: 95 °C for 30 s, 40 
cycles of denaturation at 95 °C for 5 s, annealing at 60 °C 
for 30 s, and extension at 72 °C for 15 s. PCR was carried 
out using the Real-Time PCR Detection System Rotor-
Gene 6000 (Corbett Research, Mortlake, NSW, Australia). 
Relative expression levels were calculated as ratios normal-
ized against those of 18S rRNA or U6 snRNA. The data 
from real-time qPCR were analyzed by the ΔCt method, 
and the ΔCt value was determined by subtracting the 18S 
rRNA Ct value from the target gene Ct value or the U6 
snRNA Ct value from the target miRNA Ct value. The ΔCt 
of the treated cells (ΔCts) was subtracted from the ΔCt of 
the untreated cells (ΔCtu) (ΔΔCt = ΔCts – ΔCtu), and the 
expression level for a target gene or miRNA in the treated 
cells compared with the level in the untreated cells was cal-
culated as follows: x-fold of untreated control = 2−Ct.
Western blot analysis
Cells were washed with PBS and lysed with mammalian 
protein extraction reagent from M-PER (Thermo Fisher 
Scientific, Waltham, MA, USA) supplemented with pro-
tease inhibitor mixture tablet (Roche, Indianapolis, IN, 
USA). Protein concentrations were determined by BCA 
protein assay (Thermo Fisher Scientific). For western 
blots, total proteins (30–50  μg) were resolved by 12  % 
SDS-PAGE gel and transferred to polyvinylidene fluoride 
membranes (Millipore, Bedford, MA, USA). Membranes 
were blocked with 5 % non-fat milk for 1 h at room tem-
perature and incubated with primary antibody diluted in 
2 % non-fat milk at 4  °C overnight, followed by incuba-
tion with the second antibody conjugated to horseradish 
peroxidase (HRP) for 1 h at room temperature and meas-
ured with the enhanced chemiluminescence system (Per-
kin-Elmer Life and Analytical Sciences, Waltham, MA, 
USA) and recorded on X-ray films (Fuji, Tokyo, Japan). 
Protein expression was normalized by β-actin. Primary 
antibodies used for blotting were anti-p65 (Cell Signal-
ing Technology, Beverly, MA, USA), anti-Flag (Sigma, St 
Louis, MO, USA), and anti-β-actin (Cell Signaling Tech-
nology). Anti-rabbit IgG-HRP (Cell Signaling Technol-
ogy) were used to detect primary antibodies.
Immunofluorescence
Cells were washed with PBS, then fixed with 4 % formalde-
hyde in PBS for 20 min, and finally permeabilized with 0.2 % 
Triton X-100 solution for 5 min. Cells were incubated with 
anti-Flag antibody for 1 h, washed three times with PBS, and 
then incubated with appropriate Alexa Fluor 555-conju-
gated secondary antibody and washed again three times in 
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PBS. Coverslips were mounted with ProLong Gold antifade 
reagent with DAPI (Invitrogen), and examined using a Leica 
fluorescence microscope (Leica, Wetzlar, Germany).
In vitro osteoblastogenesis and cell staining
Cells (C2C12/Runx2Dox and C2C12/VectorDox cells) were 
cultured in DMEM containing Dox, β-glycerophosphate 
disodium (10  mM) and ascorbic acid (50  μg/ml). The 
medium was changed every 3  days. For ALP staining 
and Alizarin red staining, the detailed procedures were 
described previously [48, 49].
Transfection
To examine the effect of miR-690 on Runx2-induced 
osteogenic differentiation, the miR-690 mimics and anti-
miR-690 oligos purchased from GenePharma (Shang-
hai, China) were used to promote and inhibit miR-690 
activity, respectively. Negative controls (miR and anti-
miR control) were used for both reactions. To examine 
the effect of p65 and IL-6 on Runx2-induced osteogenic 
differentiation, the cDNAs encoding mouse full-length 
p65 and IL-6 were obtained by PCR and cloned into the 
expression vector pcDNA3.1 (Invitrogen), and the IL-
6-targeting siRNA oligos (si-IL-6) was purchased from 
Sigma. Negative controls (pcDNA3.1 and si-NC oligos) 
were also used for these reactions. For transfection, Lipo-
fectamine 2000 (Invitrogen) was mixed with above-men-
tioned RNAs (50  nM/100  nM) or vectors (2.5  μg/well) 
according to the manufacturer’s instructions, and these 
solutions were directly mixed with C2C12/Runx2Dox cells 
in 6-well culture plates. For osteogenic differentiation, 
the medium was replaced with fresh medium containing 
10 % FBS and 10 μg/ml of Dox at 4 h after transfection.
Luciferase reporter assay
A 697-bp fragment of the p65 3′UTR containing the pre-
dicted binding sites for miR-690 was amplified from 
mouse genomic DNA using specific primers. Amplicon 
was cleaved with XhoI and NotI (MBI Fermentas, Burl-
ington, ON, Canada) and cloned in between the XhoI 
and NotI cleavage sites of psiCHECK-2 vector (Promega, 
Madison, WI, USA) downstream of the Renilla lucif-
erase reporter gene. The resulting construct was named 
psiCHECK-2-p65. MiR-690 (50 nM), miR-690-mut (mim-
ics containing a mutated miR-690 seed sequence, 50 nM) 
(GenePharma), or miR control (50 nM) was co-transfected 
with psiCHECK-2-p65 reporter (200  ng) into C2C12/
Runx2Dox cells using Lipofectamine 2000. After 48 h, firefly 
and renilla luciferase activity were measured in cell lysates 
using a Dual-Luciferase Reporter Assay System (Promega) 
on a Fusion plate reader (Perkin-Elmer life and Analytical 
Sciences). Firefly luciferase activity was used for normali-
zation and as an internal control for transfection efficiency.
EMSA
Nuclear extracts were prepared from Dox-treated 
C2C12/Runx2Dox cells according to the manufacturer’s 
instructions (Active Motif, Carlsbad, CA, USA). EMSA 
was performed using the EMSA kit (Promega). For 
supershift assays, an antibody against Flag-Runx2 (anti-
Flag antibody) (Sigma) or normal mouse IgG (Sigma) 
was added to the reaction mixture and incubated 25 min 
before the addition of the labeled oligonucleotide. All 
DNA–protein complexes were resolved by electrophore-
sis on 5 % native polyacrylamide gels and transmembrane 
to immobilon-Ny + (Millipore).
ChIP assay
ChIP assay was performed according to the manufactur-
er’s instructions (Active Motif ). Briefly, the crosslinked 
protein-DNA complexes prepared from Dox-treated 
C2C12/Runx2Dox cells were incubated with 4  μg of the 
anti-Flag antibody (Sigma) or normal mouse IgG (Sigma) 
and rotated at 4  °C overnight, and then were incubated 
with protein G beads at 4  °C for 4  h. The complexes 
were eluted with buffer containing 1  % SDS and 0.1  M 
NaHCO3, and crosslinks were reversed at 65  °C. DNA 
was recovered by phenol–chloroform extraction and 
ethanol precipitation and then subjected to PCR analysis. 
Amplified products were electrophoresed through 2  % 
agarose gel and visualized by Goldview staining.
Statistical analysis
All data were expressed as the mean ±  standard devia-
tion (SD) (n = 3), and statistical analysis was performed 
using SPSS software (version 16.0, Chicago, USA). Differ-
ences between two groups were analyzed by the unpaired 
Student’s t test, and differences between multiple groups 
were analyzed by ANOVA. P < 0.05 was considered sta-
tistically significant.
Additional files
Additional file 1: Figure S1. C2C12/Runx2Dox cells are actually the wild 
type C2C12 myogenic progenitor cells in the absence of Dox. (A) C2C12/
Runx2Dox cells were cultured in medium containing 2 % horse serum for 
different times. Total RNA prepared from cells at the indicated times was 
subjected to real-time qPCR analysis. Data are presented as mean ± SD 
(n = 3). *P < 0.05 compared with untreated cells (0 d). (B) C2C12/Runx2Dox 
cells were treated with Dox and BMP-2 for 9 days respectively, and the ALP 
activity was determined by ALP staining. Similar results were obtained in 
three independent experiments.
Additional file 2: Figure S2. The expression of Flag-Runx2 and Myog 
during Runx2-induced osteogenic differentiation. (A) C2C12/Runx2Dox 
cells were treated with Dox for the times indicated and subjected to 
western blot analysis with anti-Flag antibody to detect Flag-Runx2. Similar 
results were obtained in three independent experiments. (B) C2C12/Runx-
2Dox cells were treated with Dox for the times indicated and subjected to 
real-time qPCR analysis for Myog mRNA. Data are presented as mean ± SD 
(n = 3). *P < 0.05 compared with untreated cells (0 h).
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cells; DMEM: Dulbecco’s modified Eagle medium; FBS: fetal bovine serum; HRP: 
horseradish peroxidase; SD: standard deviation.
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